CancerDrs

Breast Cancer clinical trials in Hawaii

7 actively recruiting breast cancer trials at 5 sites across Hawaii.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Academic/Other

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radi…

Sponsor: NRG Oncology
NCT ID: NCT04852887
Sites in Hawaii:
  • Hawaii Cancer Care Inc - Waterfront Plaza — Honolulu, Hawaii
  • Queen's Cancer Cenrer - POB I — Honolulu, Hawaii
  • Queen's Medical Center — Honolulu, Hawaii
  • Straub Clinic and Hospital — Honolulu, Hawaii
  • University of Hawaii Cancer Center — Honolulu, Hawaii
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06876714
Sites in Hawaii:
  • Kaiser Permanente Moanalua Medical Center — Honolulu, Hawaii
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizuma…

Sponsor: AstraZeneca
NCT ID: NCT06103864
Sites in Hawaii:
  • Research Site — Honolulu, Hawaii
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.

Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT07085767
Sites in Hawaii:
  • Clinical Trial Site — Honolulu, Hawaii
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Hawaii:
  • Hawaii Cancer Care Inc - Waterfront Plaza — Honolulu, Hawaii
  • Queen's Cancer Cenrer - POB I — Honolulu, Hawaii
  • Queen's Medical Center — Honolulu, Hawaii
  • Straub Clinic and Hospital — Honolulu, Hawaii
  • University of Hawaii Cancer Center — Honolulu, Hawaii
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer

The purpose of this study is to determine the maximum tolerated dose (MTD) of OTS167 administered via oral capsule (PO) to patients with relapsed/refractory locally advanced or metastatic breast cancer.

Sponsor: OncoTherapy Science, Inc.
NCT ID: NCT02926690
Sites in Hawaii:
  • Kapi'olani Medical Center for Women & Children — Honolulu, Hawaii
View on ClinicalTrials.gov →
Recruiting Industry

EXoPERT EMERALD Clinical Study

The purpose of this study is to establish a multi-center clinical repository of blood samples to support the development and evaluation of an artificial intelligence-based in vitro diagnostic software. The software analyzes surface-enhance…

Sponsor: EXoPERT
NCT ID: NCT07186296
Sites in Hawaii:
  • University of Hawaii Cancer Center — Honolulu, Hawaii
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-07